Zydus, Lupin enter licensing pact to market drug to treat liver disease
Zydus Lifesciences and Lupin on Friday announced signing of licensing and supply agreement to market Zydus' novel drug Saroglitazar Mg for the treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steato Hepatitis (NASH) in India.
Under the terms of this agreement, Lupin will have semi-exclusive rights to co-market the product in India under the brand name LINVAS.
Zydus launched the drug under the brand names Lipaglyn and Bilypsa and will continue to market them.
Lupin will pay Zydus upfront licensing fees and milestone payments based on the achievement of pre-defined milestones.
With a once-daily, 4mg dose regimen, Saroglitazar Mg enables better compliance, reduces pill burden, and offers greater convenience for patients.
«Saroglitazar Mg which is one of the critical treatments for patients with NAFLD and NASH has substantially improved the patients’ quality of life. We are pleased to join hands with Lupin to enable access to this novel drug and thereby expand the reach,» said Dr.
Sharvil Patel, MD of Zydus.
«This partnership reaffirms our commitment to grow and expand our offerings to meet unmet needs of patients in India. This partnership will further enhance our gastroenterology portfolio, offering better access to healthcare options to our patients and medical professionals,» said Nilesh Gupta, MD of Lupin.
Zydus has been expanding access of its novel therapies through licensing agreements with other pharmaceutical companies.
